ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis

BACKGROUND: First-episode psychosis (FEP) may lead to a progressive, potentially disabling and lifelong chronic illness; however, evidence suggests that the illness course can be improved if appropriate treatments are given at the early stages. Nonetheless, the efficacy of antipsychotic medications...

Descripción completa

Detalles Bibliográficos
Autores principales: Cotton, S. M., Berk, M., Watson, A., Wood, S., Allott, K., Bartholomeusz, C. F., Bortolasci, C. C., Walder, K., O’Donoghue, B., Dean, O. M., Chanen, A., Amminger, G. P., McGorry, P. D., Burnside, A., Uren, J., Ratheesh, A., Dodd, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883553/
https://www.ncbi.nlm.nih.gov/pubmed/31779696
http://dx.doi.org/10.1186/s13063-019-3786-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883553/
https://www.ncbi.nlm.nih.gov/pubmed/31779696
http://dx.doi.org/10.1186/s13063-019-3786-5

Ejemplares similares